%A Voigtländer,Lisa %A Seiffert,Moritz %D 2018 %J Frontiers in Cardiovascular Medicine %C %F %G English %K TAVI,TAVR,Intermediate risk,Low risk,Aortic Valve Stenosis %Q %R 10.3389/fcvm.2018.00092 %W %L %M %P %7 %8 2018-July-12 %9 Review %# %! TAVI in low-intermediate risk %* %< %T Expanding TAVI to Low and Intermediate Risk Patients %U https://www.frontiersin.org/articles/10.3389/fcvm.2018.00092 %V 5 %0 JOURNAL ARTICLE %@ 2297-055X %X TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges—particularly with regard to valve durability—need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines.